Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Stock Short Interest Report for October

Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the target of a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 77,889 shares, a drop of 46.1% from the October 15th total of 144,402 shares. Currently, 7.4% of the company’s shares are sold short. Based on an average daily trading volume, of 77,098 shares, the days-to-cover ratio is currently 1.0 days.

Bluejay Diagnostics Stock Performance

Bluejay Diagnostics stock traded down $0.10 during trading on Wednesday, reaching $2.05. 6,607 shares of the company’s stock were exchanged, compared to its average volume of 528,966. Bluejay Diagnostics has a 52-week low of $1.84 and a 52-week high of $28.00. The firm has a market cap of $2.29 million, a price-to-earnings ratio of -0.07 and a beta of 0.92. The company’s 50-day moving average is $3.01 and its two-hundred day moving average is $6.84.

Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($1.72) EPS for the quarter, beating the consensus estimate of ($3,520.00) by $3,518.28.

Analyst Upgrades and Downgrades

BJDX has been the subject of a number of research reports. Wall Street Zen downgraded Bluejay Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday, September 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Read Our Latest Stock Report on Bluejay Diagnostics

Bluejay Diagnostics Company Profile

(Get Free Report)

Bluejay Diagnostics is a medical diagnostics company focused on developing and commercializing tests for use in hospital and critical-care settings. Its products are intended to help clinicians assess patients with sepsis and other serious conditions. The company’s Symphony System is a diagnostic platform designed to measure biomarkers from blood samples. Its test portfolio has included assays for biomarkers such as interleukin-6 and procalcitonin, which can support the assessment of inflammation and infection.

See Also

Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.